Figure 3

Figure 3

Examination of the prognostic value of CysLT₁ and CysLT₂ protein expression in primary UM patient samples by digital pathology analysis. (A) Representative cores from the UM TMA designated with a score of Low, Intermediate, or High expression for CysLT₁ staining following digital analysis (Scale = 40 µm). (B) High expression of CysLT₁ (red) is associated with reduced survival from metastatic melanoma in primary UM patients (n = 49; Log-rank; p = 0.012; HR 2.755; 95% CI 1.205–6.3) (C) High expression of CysLT₁ (red) is associated with reduced overall survival in primary UM patients (n = 49; Log-rank; p = 0.011; HR 2.755; 95% CI 1.205–6.3) (D) Kaplan–Meier survival curve stratified based by high (red) or low (blue) CysLT₂ expression and death by metastatic melanoma (n = 49; Log-rank; p =0.165; HR 1.796; 95% CI 0.773–4.172). (E) Kaplan–Meier survival curve stratified based by high (red) or low (blue) CysLT₂ expression and death by any cause (n = 50; Log-rank; p =0.332; HR 1.461; 95% CI 0.674–3.167). The third quartile was used as the cut-off point for high versus low expression for all Kaplan–Meier survival curves. Number of events indicates the number of deaths due to metastatic melanoma (B,D). Number of events indicates the number of deaths due to any cause (C,E).